Returning guests Bertrand Tombal and Silke Gillessen join the podcast to dive into data from the 2024 APCCC. Special guest Bertrand Tombal of Manchester Cancer Research Centre focuses on the historic and current data of AR inhibition Christopher Cutie from J and J joins the show to discuss the SUNRISE bladder program. Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024. Drs. Maite Bourlon, Elena Castro and Cristina Suarez cover the UC topics discussed on day 1 of Uromigos Live 2024. Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024. Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024. Listen to the podcast format of the panel on radioligand data in prostate cancer from Uromigos Live 2024. Listen to the podcast format of the panel on T cell directed therapy in prostate cancer from Uromigos Live 2024. Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024. Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024. Silke joins us to discuss ESMO 2024 highlights, then the birds start singing.... Fresh off the Presidential session address, Tom discusses his data with Petros commenting. Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data. Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer. Silke Gillessen joins us to discuss her Presidential session from ESMO 2024. Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC. Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC. Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.